InvestorsHub Logo
Followers 1037
Posts 115565
Boards Moderated 13
Alias Born 06/10/2006

Re: None

Saturday, 07/10/2021 10:42:11 AM

Saturday, July 10, 2021 10:42:11 AM

Post# of 11906
Interesting. Have to put my DD cap on.

About Coeptis Therapeutics
Coeptis Therapeutics, Inc. (formerly Vinings Holdings Inc.), along with its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a pharmaceutical company focused on the development of innovative therapeutics and technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio consists of two clinical-stage drug candidates (CPT1550 and CPT60621), two approved drugs (Conjupri™ (levamlodipine) tablets and Consensi® (amlodipine and celecoxib) tablets), and the product opportunities through Coeptis' two exclusive option agreements with VyGen-Bio, Inc., for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio. Coeptis' business model is designed around maximizing the value of its current product portfolio through in-license agreements, out-license agreements, and co-development relationships, as well as entering into strategic partnerships to expand its product portfolio in new and exciting therapeutic areas such as auto-immune disease and oncology. Coeptis is headquartered in Wexford, PA.


Owner (REGISTRANT) Conjupro Biotherapeutics Inc.

https://tmsearch.uspto.gov/bin/showfield?f=doc&state=4805:tqemkl.2.1

Burke Theraputics

https://burketherapeutics.com/conjupri-tablets

It is understood that all posts on the site are to be considered opinions. They do not need to indicate this in their posts.

Readers determine the veracity of the posts they read and the credibility of other Users


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent COEP News